The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer

Purpose: The transition of prostate adenocarcinoma to a predominantly androgen receptor (AR) signaling independent phenotype can occur in the later stages of the disease and is associated with low AR expression +/− the development of small-cell or neuroendocrine tumor characteristics. As metastatic tumor biopsies are not always feasible and are difficult to repeat, we sought to evaluate noninvasive methods to identify patients transitioning toward a neuroendocrine phenotype (NEPC). Experimental Design: We prospectively studied a metastatic tumor biopsy, serum biomarkers, and circulating tumor cells (CTC, Epic Sciences) from patients with castration-resistant prostate cancer (CRPC) including those with pure or mixed NEPC histology present on biopsy. CTCs labeled with the patient's clinical status were used to learn features that discriminate NEPC patients, which was then applied to an independent cohort. Results: Twenty-seven patients with CRPC including 12 NEPC and 5 with atypical clinical features suggestive of NEPC transition were studied. CTCs from NEPC patients demonstrated frequent clusters, low or absent AR expression, lower cytokeratin expression, and smaller morphology relative to typical CRPC. A multivariate analysis of protein and morphologic variables enabled distinguishing CTCs of NEPC from CRPC. This CTC classifier was applied to an independent prospective cohort of 159 metastatic CRPC patients and identified in 17/159 (10.7%) of cases, enriched in patients with high CTC burden (P < 0.01) and visceral metastases (P = 0.04). Conclusions: CTCs from patients with NEPC have unique morphologic characteristics, which were also identified in a subset of CRPC patients with aggressive clinical features potentially undergoing NEPC transition. Clin Cancer Res; 22(6); 1510–9. ©2015 AACR.

[1]  Shuang Hou,et al.  Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases , 2015, Cancer.

[2]  P. Sternberg,et al.  Erratum: The genome and transcriptome of the zoonotic hookworm Ancylostoma ceylanicum identify infection-specific gene families , 2015, Nature Genetics.

[3]  Andrew Menzies,et al.  Analysis of the Genetic Phylogeny of Multifocal Prostate Cancer Identifies Multiple Independent Clonal Expansions in Neoplastic and Morphologically Normal Prostate Tissue , 2015, Nature Genetics.

[4]  M. Landers,et al.  Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization , 2015, Journal of circulating biomarkers.

[5]  A. Aparicio,et al.  Neuroendocrine (small-cell) carcinomas: why they teach us essential lessons about prostate cancer. , 2014, Oncology.

[6]  S. Tagawa Neuroendocrine prostate cancer after hormonal therapy: knowing is half the battle. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  F Levi,et al.  European cancer mortality predictions for the year 2014. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  M. Rubin,et al.  Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation , 2014, The American journal of surgical pathology.

[9]  T. Yap,et al.  Circulating Tumor Cells: A Multifunctional Biomarker , 2014, Clinical Cancer Research.

[10]  A. Armstrong,et al.  Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[11]  M. Rubin,et al.  Aggressive Variants of Castration-Resistant Prostate Cancer , 2014, Clinical Cancer Research.

[12]  O. McCarty,et al.  Physical biology in cancer. 2. The physical biology of circulating tumor cells. , 2014, American journal of physiology. Cell physiology.

[13]  Wai Leong Tam,et al.  The epigenetics of epithelial-mesenchymal plasticity in cancer , 2013, Nature Medicine.

[14]  P. Thall,et al.  Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer , 2013, Clinical Cancer Research.

[15]  Mehmet Toner,et al.  Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells , 2013, Science Translational Medicine.

[16]  C. la Vecchia,et al.  European cancer mortality predictions for the year 2014. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Sridhar Ramaswamy,et al.  Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition , 2013, Science.

[18]  M. Rubin,et al.  Challenges in recognizing treatment-related neuroendocrine prostate cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Weinberg,et al.  Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. , 2012, Seminars in cancer biology.

[20]  Joshua M. Kunken,et al.  Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers , 2012, Physical biology.

[21]  M. Gerstein,et al.  Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. , 2011, Cancer discovery.

[22]  Andrew J Armstrong,et al.  Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers , 2011, Molecular Cancer Research.

[23]  S. Horvath,et al.  Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance , 2010, Nature Medicine.

[24]  Peter Kuhn,et al.  Cytomorphology of Circulating Colorectal Tumor Cells:A Small Case Series , 2010, Journal of oncology.

[25]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Epstein,et al.  Small Cell Carcinoma of the Prostate: A Morphologic and Immunohistochemical Study of 95 Cases , 2008, The American journal of surgical pathology.

[27]  J. Nieva,et al.  Case study of the morphologic variation of circulating tumor cells. , 2007, Human pathology.

[28]  Peter Kuhn,et al.  High speed detection of circulating tumor cells. , 2006, Biosensors & bioelectronics.

[29]  P. Thall,et al.  Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[31]  M. Rubin,et al.  Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. , 2013, Neoplasia.

[32]  L. Breiman Random Forests , 2001, Machine Learning.

[33]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.